Nan Li

Founder @_DimensionCap

[Nan Li @nanli]

1/ Last March, I teamed up with @AGoulburn and @zavaindar to build a new venture firm from scratch.

Beyond excited to officially launch Dimension (@_DimensionCap), a firm completely dedicated to the intersection of technology and the life sciences.

https://t.co/vJOMRAEZi3

[Sam Sinai @samsinai]

Since two of these benchmarks are provided by us @Dyno_Tx , I can confidently comment.

- The AAV one is uncontaminated private data of a viral trait that we've been measuring for years (i.e. sharing publicly will defeat its purpose), and use it every day (required not sufficient) to design capsids that actually do work in primates. This performance provides a real lift in expertise and resources needed to do viral evolution.

- The black-box sequence design challenge is our take-home interview. Fable completely outperforms the best people in the field on given the same exact instructions as humans, again in a private task not seen on the internet. We will release this task publicly at some point.

Biology is slow. Real accomplishments take time because the bottlenecks downstream are meaningful.

But dismissing both the upside and the risk is highly premature. They've accomplished about as much as you could imagine. In particular, being wrong on the risk is extremely costly. I for one am the most excited I've ever been that bio is going to be transformed, and agentic reasoning is a big part of why.

Also the "unknown company" is actually very well known among experts because they are all very smart/accomplished people but are not hype-y on the twitter-verse.

[Simon Barnett @SimonDBarnett]

For large pharma companies serious about integrating ML throughout their organizations, I believe they'll need infrastructure like what @tamarindbio has created.

With so many open and closed source solutions, a constantly changing model backdrop, pipelines that need constructing/maintaining/provisioning, etc ~ it's only going to get harder to conquer without a partner like Tamarind.

[Nan Li @nanli]

Congrats to Deniz, Sherry and @tamarindbio team on the partnership with Lilly! Excited to announce that Lilly's TuneLab model initiative will be solely powered by Tamarind's platform.

There are more high performance open and closed-source bio ML models now than ever. Tamarind has built the leading hosting and inference infrastructure to coordinate these models and run them in production for some of the largest Pharma companies in the world. Great milestone deal here and exciting times ahead. 🚀

[Deniz Kavi @kavi_deniz]

We’re proud to share that @TamarindBio has been selected to build, host, and operate the inference infrastructure layer for TuneLab2.0, the next evolution of the platform. @EliLillyandCo TuneLab is a first-of-its-kind, collaborative AI/ML drug discovery platform, bringing models trained on over $1B worth of Lilly proprietary data to the biotech ecosystem.

Tamarind will power TuneLab’s scalable drug discovery workflows and model inference.

[Zavain Dar @zavaindar]

2 years ago Chai was a small team led by @joshim5 & @jackdent working out of the Dimension offices

today they are leading the charge to reinvigorate western pharma and biotech. Lilly and Pfizer are partners. the majority of pharma queuing up..

the rate of progress: staggering

[Joshua Meier @joshim5]

Today we are announcing our collaboration with Pfizer to put Chai's frontier AI—including our latest model, Chai-3—directly into the hands of one of the world's leading pharmaceutical teams.

[Jack Dent @jackdent]

I’m delighted to announce @chaidiscovery's collaboration with @pfizer. Their scientists will deploy our AI platform to accelerate drug discovery, including early access to our latest frontier model Chai-3.

You can learn more about this partnership and our momentum in @amyfeldman's feature in @Forbes out today

https://t.co/VBoynDgPCz

[Bauer LeSavage @bauer_lesavage]

The training data market has exploded for LLMs and bio foundation models are next.

But biological data is extremely complex and requires a data generation playbook that prioritizes quality over immediate scale.

@_DimensionCap Research article live now!

https://t.co/3CqSYADLJP

[NewLimit @newlimit]

Following breakthrough results, we’re bringing longevity medicine to human trials.

We’ve raised a $435M Series C led by @foundersfund to make it happen.

Reprogramming cell age has the potential to create more healthy years for everyone. We're closer than ever to realizing it.

[Deniz Kavi @kavi_deniz]

ESMFold2 and the ESM-C family, now available for use!

We’ve partnered with @biohub (the ESM team’s new home), to provide day 1 access to their newly open-sourced series of models. The family of models show best-in-class results for structure prediction, de novo design, and protein-language model tasks.

[Sri Kosuri @srikosuri]

This is so cool!

[Nan Li @nanli]

Great post from @Convokebio mapping out the wide set of opportunities that exist in drug discovery. Most have no or suboptimal treatments, so much opportunity to develop medicines that impact patients!

[Convoke @Convokebio]

Today we're publishing our index of unmet needs in human disease: 2443 indications scored and ranked on burden of disease, prevalence, pipeline activity, and treatment burden. We hope this will help drug developers identify overlooked medical problems

https://t.co/OX4BKC8cfI

[Convoke @Convokebio]

Today we're publishing our index of unmet needs in human disease: 2443 indications scored and ranked on burden of disease, prevalence, pipeline activity, and treatment burden. We hope this will help drug developers identify overlooked medical problems

https://t.co/OX4BKC8cfI

[Nan Li @nanli]

Milestone moment for Odyssey Therapeutics as a publicly traded company! Testament to the incredible team and science behind the company and we are excited for the next chapter ahead! $ODTX

[DIMENSION @_DimensionCap]

Congrats to Gary Glick and the entire Odyssey Therapeutics team on today’s upsized IPO! We’re thrilled to deepen our partnership with the team as they aim to redefine the standard of care for patients living with autoimmune and inflammatory diseases. https://t.co/hzG6871reo

[Nan Li @nanli]

@semil @haystackvc @aashaysanghvi_ @DivyaDhulipala Congrats!!

[Nan Li @nanli]

Excited to announce @_DimensionCap's partnership with @apoorva_mehta @LakshAithani and @olshav on Abundance!

A fully-integrated AI stack to drive scientific and technical underwriting, eval'd against the real time feedback of the public markets. This is an idea whose time has come, headed by an incredible group of founders. Congrats on the launch and much more to come!

[Apoorva Mehta @apoorva_mehta]

https://t.co/Mavrl0rGww

[Nan Li @nanli]

RT @zavaindar: it's been exhilarating being a day 0 investor & partner with @apoorva_mehta @LakshAithani and @olshav as they build ABUNDAN…

[Nan Li @nanli]

Continue to be blown away at the pace of development at @tamarindbio. They are cooking!!

[Deniz Kavi @kavi_deniz]

We've launched 300+ molecular AI models on Tamarind.

Today, we're giving you the system we use to do it.

Introducing Custom Tools 🧵

[Georgia Channing @cgeorgiaw]

the blogs that @tamarindbio write legitimately make it possible to understand the whole landscape from one article

every other field needs this, and no other field has it

[Nan Li @nanli]

Secret’s out on @_DimensionCap’s very own @nikhilvnamburi! Deeply curious, truth seeking, competitive investor. Great to have him on the team!

Find an excuse to meet with him in SF, NY, or an obscure database conference near you.

[Delta Institute @DeltaInstitutes]

Join us in recognizing Delta's Rising Investors of 2026! 🎉

Congrats to the investors our community nominated as truly exceptional at the early stage. Angels, emerging fund managers, and established names alike, recognized for their track records, the depth of their writing, and their presence in the technical community.

These are the people who cut through the noise, back the right companies early, and show up as real partners to the founders they work with.

https://t.co/ghOMXmnNEe

[Deniz Kavi @kavi_deniz]

Today we announce the Tamarind Bio assay portal: The wet lab, now driven by software

We’ve partnered with @AAlphaBio, @adaptyvbio, and @Ginkgo to bring protein and antibody assays directly into Tamarind, making it much easier to move from computational design to real experimental feedback.

Protein design is not bottlenecked by generating candidates, but by validating them quickly enough to learn from them. We’re starting with the workhorse experiments: protein-protein binding affinity characterization, developability, expression, and stability.

The Assay Portal helps scientists:
Get fast, low-friction, cost-effective validation of designed proteins and antibodies, transparent pricing without needing separate MSAs
Specialize models on their own experimental data for affinity maturation, developability, and property optimization
Run lab-in-the-loop campaigns where each assay result improves the next design cycle
Turn wet lab data into model training infrastructure, including RL environments and large-scale datasets for pretraining

As computational molecular design matures, we believe integration between wet lab feedback and continuous learning will yield the highest quality results. That’s why we’re excited to bring the unique, differentiated capabilities of our partners to the leading biopharma R&D organizations.